

Docking and QSAR Studies of Some Quinazolinone Derivatives as Possible Inhibitors of Tyrosine Kinase

Fahimeh Ghasemi^{a,b}, Elham Jafari^{c,1}, Mahmoud Mirzaei^d, Karim Mahnam^e

^aDepartment of Bioinformatics and Systems Biology, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

^bMedical Image and Signal Processing Research Center, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

^cDepartment of Medicinal Chemistry, Bioinformatics Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran

^dChild Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease, Isfahan University of Medical Sciences, Isfahan, Iran

^eBiology Department, Faculty of Sciences, Shahrekord University, Shahrekord, Iran

Abstract: Quinazolinones are bicyclic fused heterocyclics that have been shown cytotoxic effects through different mechanisms in particular tyrosine kinase enzyme inhibition. Based on this, a series of quinazolinone derivatives were subjected to a quantitative structure activity relationship (QSAR) analysis, by using statistical tool, such as principal components analysis (PCA) and genetic algorithm (G.A). It was shown that GA_PLS is reliable to predict activities of new design compounds. Besides, the compounds were docked into the active site of the protein tyrosine kinase (PDB entry code:1M17) to identify the binding interactions. Among the thirty two studied compounds, five compounds showed convenient inhibitory effect. The most active compound of the studied derivatives, Q19, had a ΔG_{bind} of -9.52 kcal/mol.

Keywords: Quinazolinone; Tyrosine kinase; Docking; QSAR; GA_PLS

1. Introduction

Cancer is currently the most complicated disease although great advances have been made in its treatment and prevention [1]. Epidermal growth factor receptor is type of membrane bound tyrosine kinase receptor which regulates proliferation, differentiation and cell death. Over expression of this receptor in some cancers, and its targeted inhibition by anticancer drugs can be a way to cancer chemotherapy [2-4]. Quinazolinone scaffold has been considered as a privileged heterocycle due to diverse pharmacological properties including: antimicrobial, anticancer, anti-inflammatory and anticonvulsant effects [5-11]. This backbone has been used in many anticancer compounds especially tyrosine kinase receptor inhibitors.

Different mechanisms have been reported for their anti-cancer activity including: inhibition of the DNA repair enzyme, inhibition of EGFR [12], dihydrofolate reductase (DHFR) [9,13] or thymidylate enzyme inhibition [9,14] and inhibitory effects for tubulin polymerization [9,12]. Quinazolinone derivatives with appropriate substituents mainly amine or substituted amine on the 4th position promote activity against cancer cell lines [15]. Derivatives of substituted quinazolinone at 2, 3 or 2, 4 positions have been reported as anticancer agents [9, 16,17]. Literature surveys have shown many reports on cytotoxic activities of quinazolinone [9, 18-20]. Quantitative structure-activity relationship (QSAR) studies and molecular docking are key techniques in computational chemistry. Molecular docking can

¹ Corresponding Authors

e-mail: jafari@pharm.mui.ac.ir

predict predominant binding conformations of a ligand with three-dimensional structure of a protein [21]. In this study, QSAR method was performed on a series of 16 quinazolinone derivatives and docking was applied to study the interactions between 32 of quinazolinone derivatives with tyrosin-kinase as receptor (PDB entry code:1M17).




2. Computational Method

2.1. Data collection and calculation of molecular Descriptors

A dataset of 16 quinazolinone derivatives(Q1-Q8, Q14-Q20, Q30)with known cytotoxic activity

against HeLa cell lines were used for QSAR analysis [18-20], their corresponding structures are listed in Table 1. Molecular structures were scratched by Hyperchem version 8.0. The geometries which were optimized using PM3 algorithm then the molecules were transferred into Dragon program (developed by Milano Chemometrics and QSAR Group) (Todeschini et al., 2009) used for calculating a large number of descriptors including 6 different groups, listed in Tables2 and3. As shown in Table2, total number of extracted descriptors was 438. After that, zero mean, near constant and descriptors with correlation more than 0.9 were removed. Thus, 65 descriptors were utilized in QSAR model.

Table1.Chemical structures of quinazolinone derivatives.

Structure of compounds											
	A:Q1-Q3	R1	B:Q4-Q13	R1	R2	R3	X	C:Q14-Q29	R1	R2	R3
*Q1		H			-					-	
*Q2		Br			-					-	
*Q3		NO ₂			-					-	
*Q4		-	B	H	H	H	NH			-	
*Q5		-	B	Br	H	H	NH			-	
*Q6		-	B	H	H	H	C			-	
*Q7		-	B	H	Br	Br	C			-	
*Q8		-	B	NO ₂	H	H	C			-	
Q9		-	B	Br	H	H	C			-	
Q10		-	B	CH ₃	H	H	C			-	
Q11		-	B	F	H	H	C			-	
Q12		-	B	I	H	H	C			-	
Q13		-	B	CH(C H ₃) ₂	H	H	C			-	
*Q14		-			-			C	Br	Propyl chloride	NHCO(CH ₂) ₃ Cl

*Q15	-	-	C	H	(CH ₂) ₂ O-ethyl	NH ₂
*Q16	-	-	C	H	Propyl	NHCOCH ₂ S-4-methyl,2,4-triazole
*Q17	-	-	C	H	Phenyl	NHCOCH ₂ S-4-methyl,2,4-triazole
*Q18	-	-	C	H	Propyl	NHCOCH ₂ S-(4-Chlorophenyl)-1,3,4-oxadiazol
*Q19	-	-	C	H	Phenyl	NHCOCH ₂ S-(4-Chlorophenyl)-1,3,4-oxadiazol
*Q20	-	-	C	H	4-Nitrophenyl	NHCOCH ₂ S-(4-Chlorophenyl)-1,3,4-oxadiazol
Q21	-	-	C	Br	Propyl chloride	H
Q22	-	-	C	N O ₂	Propyl chloride	H
Q23	-	-	C	H	Propyl chloride	Phenyl
Q24	-	-	C	N O ₂	CH ₃	NH ₂
Q25	-	-	C	H	Et	NH-CH ₃
Q26	-	-	C	H	CH ₂ -CH(CH ₃) ₂	NHCOEt
Q27	-	-	C	H	Propyl	4-chlorophenyl
Q28	-	-	C	H	CH ₂ -CH(CH ₃) ₂	Phenyl
Q29	-	-	C	H	Et	NH-CH ₂ CH ₂ -Ph




Table2. The name of DRAGON blocks which descriptors were extracted

NO.	Descriptor block	Number of descriptors
1	Constitutional descriptors	48
2	Topological descriptors	119
3	Geometrical descriptors	74
4	Functional group count	154
5	Charge descriptors	14
6	Molecular properties	29
Total descriptors		438

Table3. The name and block of the selected descriptors.

NO.	Descriptor name	Meaning	Descriptor block
1	nN	Number of Nitrogen atom	Constitutional descriptors
2	nX	Number of Halogen atom	Constitutional descriptors
3	nR06	Number of 6 membered rings	Constitutional descriptors
4	nR09	Number of 9 membered rings	Constitutional descriptors
5	MSD	Mean squared distance	Topological descriptors
6	MEcc	Molecular eccentricity	Geometrical descriptors
7	ASP	Asphericity	Geometrical descriptors
8	G(O..O)	Sum of geometrical distance between O-O	Geometrical descriptors
9	Hy	Hydrophilic factor	
10	GVWAI-80	Ghose-viswanadhan-wendoloski antidepressant-like index at 80%	Molecular properties

3. Results and discussion

In order to achieve the best evaluation from the QSAR model, leave one-out internal validation and three-fold cross-validation, to partition the data randomly into 3 complementary sub samples, was applied. It is necessary to mention that cross validation was repeated for 3 times. In each period, one of the subsamples was saved as the test set, which using for evaluating the performance of the model,

and the rest of the compounds were stored as the training set. In the test set, the aim is to predict the biological activities of molecules just based on their descriptors. All of the results extracted from three different test sets were averaged to achieve a single output. Finally, this procedure was repeated until each ligand was observed for twenty times. All twenty results were averaged to predict the molecular activities. After that, genetic algorithm, as

a subset-selection step, was utilized to extract optimum descriptors. The number of generation, population size and mutation rate were set 100, 80 and 0.2, respectively. Multiple linear regression was used as a fitness function. In the prediction step, partial least square method (PLS) was utilized.

3.1. Metrics

Two different standard metrics, i.e. mean squared error and Pearson correlation coefficient, were used to evaluate the performance of the 2D-QSAR model between the predicted and observed activities in the test sets.

$$MSE = \frac{(Y_i - \hat{Y}_i)^2}{n}$$

$$R = \frac{\sum(Y_i - \bar{Y})(\hat{Y}_i - \bar{\hat{Y}})}{\sqrt{\sum(Y_i - \bar{Y})^2 \sum(\hat{Y}_i - \bar{\hat{Y}})^2}}$$

where n, Y and \hat{Y} are the number of molecules, the real and predicted values, respectively.

3.2. Considering the best number of descriptors with GA algorithm

First of all, it was tried to find out the best number of descriptors which had to be extracted via GA

algorithm. To predict survival values, MLR method was applied. The results of the model were presented for the test set in Figure 1.




Figure 1. Finding out the best number of extracted descriptors via GA algorithm. As shown, according to the correlation and RMST, the best result was achieved with 16 descriptors.

As shown, according to the correlation and RMST, the best result was achieved with 10 descriptors. The list of extracted descriptors were reported in Table3.

In order to consider the relationship between selected descriptors, the correlations between them were computed (Table4).

Table4. The computed correlation matrix between the selected descriptors.

	nN	nX	nR06	nR09	MSD	MEcc	ASP	G(O..O)	Hy	GVWAI-80
nN	1	0.52	0.36	-0.57	0.01	-0.62	-0.02	-0.29	-0.09	-0.52
nX	0.52	1	-0.47	0.35	0.09	-0.32	0.33	0.25	-0.25	0.454
nR06	0.36	-0.47	1	-0.90	0.14	-0.28	-0.29	-0.84	-0.01	-0.85
nR09	-0.57	0.35	-0.90	1	-0.14	0.27	0.34	0.66	0.06	0.95
MSD	0.01	0.09	0.14	-0.14	1	0.29	0.22	-0.32	-0.73	0.08
MEcc	-0.62	-0.32	-0.28	0.27	0.29	1	0.01	0.18	-0.18	0.32
ASP	-0.02	0.33	-0.29	0.34	0.22	0.01	1	0.20	-0.20	0.36
G(O..O)	-0.29	0.25	-0.84	0.66	-0.32	0.18	0.20	1	0.14	0.56
Hy	-0.09	-0.25	-0.01	0.06	-0.73	-0.18	-0.20	0.14	1	-0.15
GVWAI-80	-0.52	0.45	-0.85	0.95	0.08	0.32	0.36	0.56	-0.15	1

3.3. Investigating the performance of the PLS components

As mentioned in previous section, partial least square method was utilized to estimate survival of molecules. In order to investigate performance of

the PLS with respect to different components, the Pearson correlation coefficient were sketched in the Figure 2. As shown, the best value of the error was achieved with 6 components.




Figure 2. The performance of the PLS method based on different components. The best value is indicated by blue circle

3.4. Investigating the impact of proposed QSAR model

At the second step, it was attempted to consider impact of GA-PLS model for the survival prediction in concentration 100 μ M. The results of the proposed model were presented for the training set and the test set in Figure 3. The correlation of the training set and the test set were 0.87 and 0.81, respectively. Therefore, it is shown that the proposed model could be appropriate to predict the activities of the new compounds.




Figure 3. Real variable versus predicted variable of all compounds.

Since the nature of proposed model consisted two main parts, i.e. descriptor selection and activity prediction, the impact of the GA on the model output was investigated (Figure 4). Each model was run for twenty times. The results showed that extracting the optimum descriptors could be affected on the network results.




Figure 4. Comparison between the range of PLS and GA-PLS. It is obvious that the mean and the range of GA-PLS are less than PLS. Thus, GA-PLS is more reliable than the PLS to predict molecular activity.

3.5. Docking results

Energy-based interactions (ΔG_b) and inhibition constants (K_i) between quinazolinone derivatives and tyrosine kinase summarized in table 5. According to the data presented in this table ligands interact with the tyrosine kinase binding site through hydrogen bonding. Among 6- or 5-membered ring fused quinazolinones (series A, B, Q₃₁, Q₃₂), compounds Q₃, Q₇ and Q₈ showed the lowest binding energy and estimated inhibition constant. The conjugated oxadiazole-quinazolinone derivatives with amide linker revealed the lowest binding energy and estimated inhibition constant in the nanomolar range among 2, 3-disubstituted 4(3H)-quinazolinone derivatives (Q₁₄-Q₂₉, Q₃₀). Figure 5 show 3D schematic presentations of compounds Q₃, Q₇, Q₈ and Q₁₉ while docked into the the tyrosine kinase binding site.

Inhibition of EGFR is one of the suggested mechanisms for anti-cancer activity of quinazolinones and over expression of this receptor in some cancers was observed [26,2,3]. According to these concepts, in this study, quinazolinone derivatives were divided into three categories based on structure including 5-membered ring-fused quinazolinones, 6-membered ring fused quinazolinones and 2, 3-disubstituted 4(3H)-quinazolinone derivatives. These analogs were docked into the active site of the tyrosin-kinase as receptor (PDB entry code:1M17) to identify the binding interactions responsible for cytotoxic activity. As shown in table 5, among tricyclic quinazolinone derivatives, (series A, B, Q₃₁, Q₃₂) compounds Q₃, Q₇ and Q₈ showed the lowest

binding energy -6.12, -6.16 and -6.10 kcal/mol respectively and the lowest estimated inhibition constant. This result is in accordance with the experimental results previously reported [18].

Table 5. Energy-based interactions (ΔG_b) and inhibition constants (Ki) for 32 of quinazolinone derivatives docked into tyrosine kinase

No.	R ₁	ΔG_b (kcal/mol)	Hydrogen bond (Distance, Å)	Ki (μ M)
Q ₁		-5.47	Lys 721 (2.07)	97.07
Q ₂		-5.96	Met 769 (1.68)	42.75
Q ₃		-6.12	Met 769 (1.60), Lys 704 (1.86)	32.87
Q ₄		-5.15	-	168.18
Q ₅		-5.82	Thr 766 (2.22)	54.40
Q ₆		-5.03	Lys 721 (2.04)	206.74
Q ₇		-6.16	Gln 767	30.78
Q ₈		-6.10	Lys 704 (2.05), Met 769 (2.03)	33.58
Q ₉		-5.59	Met 769 (1.78)	80.38
Q ₁₀		-5.36	Met 769 (1.78)	116.97
Q ₁₁		-4.95	Met 769 (1.76)	233.55
Q ₁₂		-5.78	Thr 766 (2.04)	57.97
Q ₁₃		-6.05	Met 769 (1.78)	36.79
Q ₁₄		-8.13	Met 769 (2.15)	1.1
Q ₁₅		-5.92	Lys 721 (2.02)	45.91
Q ₁₆		-7.39	Lys 721 (1.90), Met 769 (1.01)	3.81
Q ₁₇		-6.27	Met 769 (1.92)	25.45
Q ₁₈		-9.16	Met 769 (1.703), Cys 773 (2.06)	191.8 nM
Q ₁₉		-9.52	Cys 773 (2.1), Asp 776 (2.11)	104.93 nM
Q ₂₀		-9.08	Met 769 (1.89), Asp 776 (1.92)	221.45 nM
Q ₂₁		-5.76	Gln 767 (2.08)	60.13
Q ₂₂		-6.07	Met 769 (1.83)	35.71
Q ₂₃		-7.19	-	5.37
Q ₂₄		-5.97	Met 769 (2.0)	41.94
Q ₂₅		-5.50	Lys 721 (1.99)	92.63
Q ₂₆		-6.40	Lys 721 (2.12)	20.25
Q ₂₇		-6.95	-	8.09
Q ₂₈		-7.08	-	6.43
Q ₂₉		-7.54	Met 769 (2.0)	2.95
Q ₃₀		-6.47	Glu 738 (2.15)	18.2
Q ₃₁		-5.86	Met 769 (1.96)	50.97
Q ₃₂		-5.69	Met 769 (1.63)	67.61

Two compounds Q₃ and Q₈ can create strong hydrogen bond with Lys 704 via nitro electron withdrawing substitution on the phenyl ring at distance (1.86-2.05 Å) and Met 769 via carbonyl group of quinazolinone. The best result of docking studies was observed for oxadiazole-quinazolinone derivatives with amide linker (Q₁₈-Q₂₀) categorized in 2, 3-disubstituted 4(3H)-quinazolinone group. The lowest dock score for these series was -9.52 kcal/mol for compound Q₁₉. Rest of 2, 3-disubstituted 4(3H)-quinazolinone showed a proper dock scores ranging from -5.5 to -8.13 kcal/mol. Two hydrogen binding interactions have been detected for Q₁₉ ligand. Cys 773 and Asp 776 are the responsible amino acids for

formation of hydrogen binds. Oxygens of oxadiazole ring and amid linker has been participated in a hydrogen bond interaction with Cys 773 and nitrogen atoms of the 1,3,4-oxadiazole ring has been formed hydrogen binding with Asp 776. Q₁₈ also showed acceptable dock score and hydrogen binding with Met 769 and Cys 773 residues. This compound showed the highest cytotoxic activities with the IC₅₀ value of 7.52 μ M against HeLa cell line [19].

At the second step, it was attempted to model proposed structures and found out the main effective descriptors on the biological output. It seems that number of Nitrogen atom (nN), number of 6 or 5 membered rings (nR₀₅ and nR₀₆), mean

squared distance (MSD), molecular Eccentricity (MEcc), A sphericity (ASP), sum of geometrical distance between o-o (G(o..o)) were important on the results. Finally, the QSAR model based on the

extracted descriptors was created via partial least square model. It is hope that the proposed model will be helpful on the future of design new compounds as the EGF inhibitors.




Figure 5. Docked conformation of compounds (A)Q₃, (B)Q₇, (C) Q₈and (D) Q₁₉in the binding site of epidermal growth factorreceptor tyrosine kinase. Hydrogen bonds are shown by the black dashed line.

4. Conclusion

Based on the obtained results of docking and in-vitro cytotoxic assay compounds Q₃, Q₇, Q₈, Q₁₈ and Q₁₉ could be introduced as anticancer agents via tyrosine kinase inhibition pathways. Besides, according to the QSAR model, it seems that number of Nitrogen atom and rings, centrality and geometrical distance between two oxygen are the main properties which must be noted to design new molecules in the future of work. But, in vitro

inhibitory study against tyrosine kinases are necessary to complete this finding.

Conflict of interest statement

Authors declare no conflict of interest.

Acknowledgements

This work was financially supported under grant number 295225 by the Bioinformatics Research Center, School of Pharmacy and Pharmaceutical

Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.

References

- [1] S. Ranjbar, N. Edraki, M. Khoshneviszadeh, A. Foroumadi, R. Miri, M. Khoshneviszadeh.. Design, synthesis, cytotoxicity evaluation and docking studies of 1, 2, 4-triazine derivatives bearing different arylidene-hydrazinyl moieties as potential mTOR inhibitors, *Res. Pharm. sci.* 13(1), (2018) 1-11.
- [2] X. Qin, Z .Li, L. Yang, P. Liu, L. Hu, C. Zeng, Z. Pan. Discovery of new [1, 4] dioxino [2, 3-f] quinazoline-based inhibitors of EGFR including the T790M/L858R mutant, *Bioorg & Med Chem.* 24 (2016) 2871-2881.
- [3] X. Qin, Y. Lv, P. Liu, Z .Li, L. Hu, C. Zeng, L. Yang. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors *Bioorg & Med Chem Lett.* 26 (2016) 1571-5.
- [4] A.S. Shaw, A.P. Kornev, J. Hu, L.G. Ahuja, S.S. Taylor. Kinases and pseudokinases: lessons from RAF. *Mol. Cell. Biol.* 34 (2014) 1538-46.
- [5] G. Vaseghi, E. Jafari, F. Hassanzadeh, S. Haghjooy-Javanmard, N. Dana, M. Rafieian-Kopaei. Cytotoxic evaluation of some fused pyridazino-and pyrrolo-quinazolinones derivatives on melanoma and prostate cell lines. *Adv. Biomed. Res.* 6 (2017):1-4.
- [6] T. Elavarasan, D. Bhakiarajand, M. Gopalakrishnan. Antimicrobial screening and molecular docking studies of some novel triazoloquinazolinone derivatives. *Der Pharm. Chem.* 6 (2014) 391-400.
- [7] E. Jafari, G.A. Khodarahmi, F. Hassanzadeh, G.H. Hakimelahi, F. Tsai. Synthesis of some new tricyclic 4 (3H)-quinazolinone derivatives. *Res. Pharm. Scie.* 6 (2011) 93-100.
- [8] M.A. Mohamed, H.M. Ghanem, N.F. Abd El-Ghaffar, S.S. Mohamed. Biological evaluation and molecular docking of substituted quinazolinones as antimicrobial agents. *Aust J Basic Appl Sci.* 7 (2013) 263-74.
- [9] G.A. Khodarahmi, M.R. Khajouei, G.H. Hakimelahi, D. Abedi, E. Jafari, F. Hassanzadeh. Antibacterial, antifungal and cytotoxic evaluation of some new 2, 3-disubstituted 4 (3H)-quinazolinone derivatives. *Res. Pharm. Scie* 7 (2012) 151-158.
- [10] F. Hassanzadeh, M.R. Khajouei, G.H. Hakimelahi, E. Jafari, G.A. Khodarahmi. Synthesis of some new 2, 3-disubstituted-4 (3H) quinazolinone derivatives. *Res. Pharm. Scie* 7 (2012) 23-30.
- [11] G.A. Khodarahmi, E. Jafari, G.H. Hakimelahi, D. Abedi, M.R. Khajouei, F. Hassanzadeh. Synthesis of some new quinazolinone derivatives and evaluation of their antimicrobial activities. *Iran. J. Pharm. Sci.* 11.(2012)789-797.
- [12] E. Jafari, M.R. Khajouei, F. Hassanzadeh, G.H. Hakimelahi, G.A. Khodarahmi.. Quinazolinone and quinazoline derivatives: recent structures with potent antimicrobial and cytotoxic activities *Res. Pharm. Scie* 11 (2016) 1-14.
- [13] M.E. Sahu, A.G. Nerkar. In silico screening, synthesis and in vitro evaluation of some quinazolinone derivatives as dihydrofolate reductase inhibitors for anticancer activity: Part-I. *International . Int. J Pharm & . Pharm. Sci* 6 (2014) 193-9.
- [14] V. Srivastava, S.P. Gupta, M.I. Siddiqi, B.N. Mishra. Molecular docking studies on quinazoline antifolate derivatives as human thymidylate synthase inhibitors. *Bioinformation.* 4 (2010) 357-365.
- [15] P.M. Chandrika, T. Yakaiah, B. Narsaiah, V. Sridhar, G .Venugopal, J .Venkateshwara rao, et al.. Synthesis leading to novel 2, 4, 6-trisubstituted quinazoline derivatives, their antibacterial and cytotoxic activity against THP-1, HL-60 and A375 cell line. *Indian J. Chem.* 48B(2009) 840-7.
- [16] K. Srivalli, K. Satish. Synthesis, In Vitro Evaluation of Some Novel Quinazolin-4 (3H)-one Derivatives as Anti-Tumor Agents. *Chem. Sci. Trans.* 1(2012) 624-31.

- [17] L. Hosseinzadeh, A. Aliabadi, M. Rahnama, H.M. Sadeghi, M.R. Khajouei. Synthesis and cytotoxic evaluation of some new 3-(2-(2-phenylthiazol-4-yl) ethyl)-quinazolin-4 (3H) one derivatives with potential anticancer effects. *Res. Pharm. Scie* 12(2017) 290-298.
- [18] F. Hassanzadeh, E. Jafari, G.H. Hakimelahi, M.R. Khajouei, M. Jalali, G.A. Khodarahmi. A. Antibacterial, antifungal and cytotoxic evaluation of some new quinazolinone derivatives. *Res. Pharm. Scie* 7.(2012) 87-94.
- [19] F. Hassanzadeh, H. Sadeghi-Aliabadi, E. Jafari, A. Sharifzadeh, N. Dana. Synthesis and cytotoxic evaluation of some quinazolinone-5-(4-chlorophenyl) 1, 3, 4-oxadiazole conjugates. *Res. Pharm. Scie*, 14 (2019) 408-413.
- [20] F. Hassanzadeh, H. Sadeghi-Aliabadi, S. Nikooyei, E. Jafari, G. Vaseghi. Synthesis and cytotoxic evaluation of some derivatives of triazole-quinazolinone hybrids. *Res. Pharm. Scie* 14 (2019) 130-137.
- [21] F. Ghasemi, A. Mehridehnavi, A. Perez-Garrido, H. Perez-Sanchez,, Neural network and deep-learning algorithms used in QSAR studies: merits and drawbacks, *Drug Discov.* 23 (2018)1784-1790.
- [22] T. Mostashari-Rad, R. Arian, H. Sadri, A. Mehridehnavi, M. Mokhtari, F. Ghasemi, A. Fassihi, Study of CXCR4 chemokine receptor inhibitors using QSPR and molecular docking methodologies, *J. Theor. Comput. Chem.* 18 (2019)
- [23] F. Ghasemi, A. Mehri, J. Peña-García, H. den-Haan, A. Pérez-Garrido, A. Fassihi, H. Pérez-Sánchez, Improving Activity Prediction of Adenosine A2B Receptor Antagonists by Nonlinear Models, *Int. Conf. Bioinform. Biomed. Eng.*(2015) 635-644
- [24] F. Hassanzadeh, E. Jafari, M. Zarabi, G. Khodarahmi, G. Vaseghi. Synthesis, cytotoxic evaluation, and molecular docking studies of some new 1, 3, 4-oxadiazole-based compounds. *Res. Pharm. Scie*.15 (2020) 454-62.
- [25] A Ousaa. QSAR and docking studies on the pyrimidine derivatives analogs with antileishmanial activity. *RHAZES: Green. App. Chem.*1 (2018) 50-63.
- [26] A.Y. Helali, M.T. Sarg, M.M. Koraa, M.S. El-Zoghbi.,. Utility of 2-methyl-quinazolin-4 (3H)-one in the synthesis of heterocyclic compounds with anticancer activity. *Open. J. Medi. Chem* 28(2014) 12-37.